WeVote
Log In

Bill

Bill

A 1445

Provides for rules and regulations for state aid reimbursement for the purchase of opioid antagonists by municipalities

2025 Regular Session Introduced by Linda Rosenthal

Creates a state-funded program to reimburse municipalities for naloxone purchases, with rules and oversight to improve access to overdose antidotes and public safety.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 1445

Summary of Assembly Bill A 1445

Overview

Bill A 1445 would establish a state-supported framework to reimburse municipalities for the purchase of opioid antagonists (e.g., naloxone) and to regulate how such reimbursements are administered. The bill is introduced in the New York Assembly and, as of the provided information, has been referred to the Health Committee. The primary sponsor is Linda Rosenthal.

Purpose and Intent

  • Create a formal program for state aid reimbursements to municipalities that purchase opioid antagonists.
  • Implement rules and regulations governing the eligibility, administration, and oversight of the reimbursement process.
  • Support public safety and public health responses to opioid overdoses by improving access to antidotes at the municipal level.

Key Provisions (as inferred from the bill’s title and status)

  • Rulemaking Authority: The bill would authorize the appropriate state agency (likely the Department of Health or a similar entity) to promulgate rules and regulations to govern the reimbursement program.
  • Reimbursement Framework: Establish the mechanism by which municipalities can seek state aid reimbursement for eligible opioid antagonist purchases.
  • Eligibility and Documentation: Provide criteria for which purchases are eligible and the documentation or records municipalities must submit to receive reimbursement.
  • Administration and Oversight: Create processes for application, approval, and ongoing oversight, including potential audits or compliance checks.
  • Funding and Fiscal Considerations: Indicate that reimbursements would be funded by state resources, subject to appropriations and annual budget decisions.
  • Reporting: Require reporting to monitor program utilization, expenditures, and outcomes related to opioid antagonist access and overdose prevention.

Note: The available information does not include detailed text on specific eligibility thresholds, reimbursement rates, caps, or implementation timelines. The above reflects typical elements expected in a bill of this scope based on the title and action.

Affected Parties

  • Municipalities that purchase opioid antagonists for public safety, EMS, healthcare providers, or community programs.
  • Public health and emergency response systems within municipalities.
  • State agencies responsible for administering health program reimbursements and ensuring compliance with rules.

Procedural and Timeline Aspects

  • Introduced: January 9, 2025.
  • Current Status: Referred to Health (as of the provided information). No further actions or floor votes are listed.

Related Legislation

  • Related bills from prior sessions: A 10992, A 1134, A 1516, A 516.
  • Sponsor: Linda Rosenthal (primary).

Notes

  • This summary is based on the bill’s title and the provided legislative actions. Full text would clarify exact eligibility, reimbursement rates, funding mechanisms, and implementation timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.